In the Reply Letter titled 鈥淟et Us Not Forget the Long-term Safety Concerns of Sacubitril/Valsartan鈥擱eply,鈥�1 published online March 22, 2017, and in the July 2017 issue of JAMA Cardiology, the author disclosed conflicts of interest that were inadvertently omitted. The Conflict of Interest Disclosures section should read as follows: 鈥淭he author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Packer has received personal fees from Amgen, Admittance, Bayer, Boehringer Ingelheim, Celyad, Daiichi Sankyo, Ferring, GlaxoSmithKline, Novartis, Relypsa, Sanofi, Takeda, and ZS Pharma.鈥� This article was corrected online.
1.Packer
聽M. 聽Let us not forget the long-term safety concerns of sacubitril/valsartan鈥攔eply.聽聽JAMA Cardiol. 2017;2(7):819.